ArticleAnnals of the rheumatic diseases2007
Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review.Current rheumatology reports · 2014Pooled it
- Preference-based measures of health-related quality of life in congenital mobility impairment: a systematic review of validity and responsiveness.Health economics review · 2020Review
- The 8-foot up and go test is the best way to assess physical function in the rheumatoid arthritis clinic.Rheumatology advances in practice · 2018Article
- Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies.BMC musculoskeletal disorders · 2016Observational
- The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2013Article
- Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.Rheumatology international · 2012Article
- Rheumatoid arthritis: clinical utility of the RAID (RA impact of disease) score.Nature reviews. Rheumatology · 2011Article
- Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.Clinical rheumatology · 2011Review
- Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.Health and quality of life outcomes · 2010Article
- Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.Drugs · 2010Review
- The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchArticle
- Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitis.Clinical and experimental rheumatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is growing emphasis on the cost-effectiveness of treating rheumatoid arthritis. Few trials directly record the health utility measures, like EuroQol, needed for economic analyses. Consequently linear regression methods have been used to transform Health Assessment Questionnaire (HAQ) scores into utility measures. The authors examined whether this is justified.
methodsThe authors compared HAQ and EuroQol in cross-sectional and treatment change observational studies of rheumatoid arthritis patients; they also measured SF-36 and Nottingham Health Profiles.
resultsIn the cross-sectional study, HAQ and EuroQol scores were moderately inversely correlated (Spearman rank correlation, r = 0.76). HAQ showed a Gaussian distribution whereas EuroQol was bimodal. In the treatment change study, changes in HAQ and EuroQol were unrelated (r = 0.08); the changes showed similar Gaussian and bimodal distributions.
conclusionsNot all patient-based measures are analogous, and evidence of clinical equivalence, especially in treatment response, is needed before data transformation is considered. Specifically, as HAQ and EuroQol are demonstrably not equivalent, economic evaluations of treatment cost effectiveness should not be based on EuroQol data transformed from HAQ. The use of such transformed data by regulatory bodies which determine drug availability means that the issue is no longer only of academic interest but a real clinical concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.